Prader Willi Syndrome Therapeutics Market: Is 2026 the Year We Finally Conquer Hyperphagia?
In early 2026, the Prader Willi Syndrome Therapeutics Market is valued at $575 million, marking a pivotal transition from purely hormonal management to specialized "hunger-blocking" science. This year, the industry is celebrating the first full year of commercial availability for VYKAT XR (diazoxide choline), which received landmark FDA approval in March 2025 as the first-ever treatment for...
0 Commentarios 0 Acciones 69 Views 0 Vista previa